Linking contralateral breast cancer with genetics

Radiotherapy and Oncology

Volumn 86, Issue 2, 2008, Pages 139-141

  Roukos, Dimitrios H ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; DNA STRAND BREAKAGE; EDITORIAL; FOLLOW UP; GENE MUTATION; GENETICS; HUMAN; MASTECTOMY; PRIORITY JOURNAL; QUALITY OF LIFE; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

BREAST NEOPLASMS; FAMILY HEALTH; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; INCIDENCE; MASTECTOMY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS;

EID: 39149087337     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2008.01.013     Document Type: Editorial

References (19)

1. Gralow J., Ozols R.F., Bajorin D.F., et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening a report from the american society of clinical oncology. J Clin Oncol 26 (2008) 313-325
2. Herrinton L.J., Barlow W.E., Yu O., et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23 (2005) 4275-4286
3. Tuttle T.M., Habermann E.B., Grund E.H., et al. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25 (2007) 5203-5209
4. Yadav BS, Sharma SC, Patel FD, Ghoshal S, Kapoor RK. Second primary in the contralateral breast after treatment of breast cancer. Radiother Oncol. 2007 Oct 23; [Epub ahead of print].
5. Goldhirsch A., Wood W.C., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18 (2007) 1133-1144
6. Clarke M., Collins R., Darby S., et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366 (2005) 2087-2106
7. Roukos D.H., Kappas A.M., and Agnantis N.J. Perspectives and risks of breast-conservation therapy for breast cancer. Ann Surg Oncol 10 (2003) 718-721
8. Punglia R.S., Morrow M., Winer E.P., and Harris J.R. Local therapy and survival in breast cancer. N Engl J Med 356 (2007) 2399-2405
9. Narod S.A., and Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 23 (2005) 1656-1663
10. Pierce L.J., et al. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24 (2006) 2437-2443
11. Farmer H., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
12. Roukos D.H., and Briasoulis E. Individualized preventive and therapeutic management of hereditary breast ovarian cancer. Nat Clin Pract Oncol 4 (2007) 578-590
13. Sotiriou C., and Piccart M.J. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?. Nat Rev Cancer 7 (2007) 545-553
14. Fatouros M., Baltoyiannis G., and Roukos D.H. The predominant role of surgery in the prevention and new trends in the surgical treatment of hereditary breast ovarian cancer. Ann Surg Oncol 15 (2008) 21-33
15. Roukos D.H., Murray S., and Briasoulis E. Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer. Cancer Biol Ther 6 (2007) 308-312
16. Roukos D.H. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 357 (2007) 1555-1556 author reply 1556
17. Roukos D.H. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 358 (2008) 197
18. Wood L.D., Parsons D.W., and Jones S. The genomic landscapes of human breast and colorectal cancers. Science 318 (2007) 1108-1113
19. Roukos D.H. Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Rev Mol Diagn 8 (2008) 29-39